Cubist Systematic Strategies, LLC Seres Therapeutics, Inc. Transaction History

Cubist Systematic Strategies, LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$4.67 - $6.55 $354,420 - $497,099	75,893 Added 776.96%	85,661 $410,000
Q1 2023 May 15, 2023	SELL	$4.95 - $6.09 $279,338 - $343,670	-56,432 Reduced 85.24%	9,768 $55,000
Q4 2022 Feb 14, 2023	BUY	$5.09 - $9.05 $336,011 - $597,426	66,014 Added 35491.4%	66,200 $370,000
Q3 2022 Nov 14, 2022	SELL	$3.5 - $7.2 $15,981 - $32,875	-4,566 Reduced 96.09%	186 $1,000
Q2 2022 Aug 15, 2022	SELL	$2.7 - $7.62 $104,994 - $296,318	-38,887 Reduced 89.11%	4,752 $16,000
Q1 2022 May 16, 2022	SELL	$6.3 - $8.84 $1.54 Million - $2.15 Million	-243,763 Reduced 84.82%	43,639 $311,000
Q4 2021 Feb 14, 2022	SELL	$6.02 - $11.43 $185,343 - $351,906	-30,788 Reduced 9.68%	287,402 $2.39 Million
Q3 2021 Nov 15, 2021	BUY	$5.46 - $22.6 $1.59 Million - $6.57 Million	290,499 Added 1049.07%	318,190 $2.22 Million
Q2 2021 Aug 16, 2021	BUY	$18.46 - $24.36 $511,175 - $674,552	27,691 New	27,691 $660,000
Q1 2021 May 17, 2021	SELL	$17.66 - $28.92 $281,624 - $461,187	-15,947 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$23.25 - $37.73 $1.34 Million - $2.18 Million	-57,720 Reduced 78.35%	15,947 $391,000
Q3 2020 Nov 16, 2020	BUY	$3.74 - $28.74 $190,003 - $1.46 Million	50,803 Added 222.2%	73,667 $2.09 Million
Q2 2020 Aug 14, 2020	BUY	$3.04 - $6.2 $69,506 - $141,756	22,864 New	22,864 $109,000
Q4 2017 Feb 14, 2018	SELL	$9.15 - $12.64 $96,733 - $133,630	-10,572 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$12.81 - $16.85 $135,427 - $178,138	10,572	10,572 $170,000

41M

304K

471K

Ticker MCRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,072,000
Market Cap $104M
Description
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.